1. GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines
- Author
-
Francesca Mancini, Gianmarco Gasperini, Roberto Adamo, Elena Palmieri, Paolo Costantino, Martina Carducci, Cristiana Balocchi, Renzo Alfini, Brunella Brunelli, Fabiola Schiavo, Roberta Benedetto, Allan Saul, Francesca Necchi, Diego Piccioli, and Francesca Micoli
- Subjects
0301 basic medicine ,Pharmacology ,Computer science ,Immunogenicity ,lcsh:R ,Immunology ,lcsh:Medicine ,Computational biology ,Article ,Combination vaccines ,GMMA ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Infectious Diseases ,Immune system ,Antigen ,Global distribution ,vaccine ,Drug Discovery ,Outer Membrane Vesicles (OMV) ,Pharmacology (medical) ,030212 general & internal medicine ,Bacterial outer membrane ,glycoconjugate - Abstract
Technology platforms are an important strategy to facilitate the design, development and implementation of vaccines to combat high-burden diseases that are still a threat for human populations, especially in low- and middle-income countries, and to address the increasing number and global distribution of pathogens resistant to antimicrobial drugs. Generalized Modules for Membrane Antigens (GMMA), outer membrane vesicles derived from engineered Gram-negative bacteria, represent an attractive technology to design affordable vaccines. Here, we show that GMMA, decorated with heterologous polysaccharide or protein antigens, leads to a strong and effective antigen-specific humoral immune response in mice. Importantly, GMMA promote enhanced immunogenicity compared to traditional formulations (e.g., recombinant proteins and glycoconjugate vaccines), without negative impact to the anti-GMMA immune response. Our findings support the use of GMMA as a &ldquo, plug and play&rdquo, technology for the development of effective combination vaccines targeting different bugs at the same time.
- Published
- 2020
- Full Text
- View/download PDF